The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia

HaEmek Medical Center, Israel

Status: Completed

Conditions: Thalassemia; Sickle Cell Anemia

Study type: Observational

Funder types: Other

Identifiers

NCT00971698

0135-08-EMC

Details and patient eligibility

About

The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy.

In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.

The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.

Full description

Clinical and laboratory characteristics related to the spleen in SCA patients will be studied.

Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.

In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.

Enrollment: 50 estimated patients

Sex: All

Ages: 1 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All the patients followed up at the Pediatric Hematology Unit

Exclusion criteria

• Patients lost from follow up of with insufficient data

Trial design

50 participants in 2 patient groups

Sickle Cell Patients

Description:

Patients with homozygous Sickle Cell Anemia

Sickle Cell Thalassemia

Description:

Patients with Sickle Cell Thalassemia